Scott Smith is a neurotechnology executive who has enthusiastically embraced innovation in the fields of cognitive and clinical neuroscience and neurology for over 25 years. Scott was part of the team who brought the first commercial 128 channel amplifier to market (Neuroscan Synamp), and the first FDA approved 512 channel system for recording from microelectrodes in humans (Neuralynx ATLAS). He has extensive expertise in equipping pre-clinical research studies, including human single-neuron studies. Scott is passionate about enabling research by neuroscientists and clinicians at many of the world’s leading academic facilities. He thrives on the fact that advances made in technology and knowledge today will lead to better outcomes for patients in the future.
Scott earned an MS in Psychology with a focus on cognitive neuroscience and electrophysiology from UT El Paso. After graduate school, he joined Neuroscan where he rose to the position of VP of Technical Operations. Most recently, Scott was VP of Clinical Sales at Neuralynx, Inc.
“We are excited to have Scott join the executive team at Diagnostic Biochips” said Greg Alden, President and CEO, “Scott brings a wealth of experience in the industry, a proven track record, and a shared passion to help find cures and therapies for neurodegenerative diseases and disorders.”
In his new role at Diagnostic Biochips, Scott will be responsible for leading all go-to-market activities globally, including sales, business development, and partnerships. Scott will be based in Austin, Texas where he resides with his wife Valeri. In his free time, you will find him traveling, kayaking, searching for that next unique relic, and enjoying Austin’s live music scene.